Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Co-magaldrox
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Co-magaldrox 195mg/220mg/5ml oral suspension sugar free
0101010G0AAABAB
|
Co-magaldrox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | 3,184 |
|
Co-magaldrox 200mg/175mg/5ml oral suspension sugar free
0101010G0AAAGAG
|
Co-magaldrox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | 387 |
|
Co-magaldrox 300mg/600mg tablets
0101010G0AAADAD
|
Co-magaldrox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | No data available |
|
Co-magaldrox 300mg/600mg/5ml oral suspension sugar free
0101010G0AAACAC
|
Co-magaldrox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.